By Billy Candra 
This groundbreaking methodology, pioneered by researchers from the University of British Columbia (UBC) and BC Children’s Hospital Research Institute (BCCHR), marks a significant leap forward in pediatric oncology. It represents the first instance in Canada where the combination of ex ovo tumour models and advanced proteomics has successfully identified and validated a drug candidate for a young patient’s aggressive tumour within a clinically relevant timeframe. The success, detailed in a recent publication in EMBO Molecular Medicine, underscores the immense potential of proteomics as an indispensable complement to established genomic analyses in the realm of real-time cancer therapies.
The Urgent Need for Innovation in Pediatric Oncology
Pediatric cancers, while relatively rare compared to adult cancers (affecting approximately 1,000 children and adolescents in Canada each year), present unique and often formidable challenges. Children’s cancers are biologically distinct, frequently aggressive, and can be resistant to conventional treatments. The impact on young patients and their families is profound, demanding innovative approaches to diagnosis and therapy. For those diagnosed with rare or relapsed cancers, treatment options can dwindle rapidly, leaving little time for extensive trial-and-error approaches. This exigency has driven the medical community to explore precision oncology – tailoring treatments based on the unique biological characteristics of each patient’s tumour.
Historically, precision oncology has largely relied on genomics, the study of a tumour’s genetic makeup. By identifying specific mutations or alterations in a tumour’s DNA, clinicians aim to pinpoint vulnerabilities that can be targeted with specific drugs. While genomics has revolutionized cancer treatment for many, it has its limitations, particularly in cases where genetic alterations do not directly translate into actionable therapeutic targets or where tumours develop resistance through complex mechanisms not immediately apparent at the genomic level. This critical gap spurred researchers to investigate alternative, complementary strategies.
A Novel Two-Pronged Approach: Proteomics and Avatars
The innovative strategy developed by the Canadian team tackles these challenges head-on by integrating two powerful techniques: advanced proteomics and patient-derived ex ovo tumour avatars. Proteomics involves the large-scale study of proteins, the functional workhorses of our cells, which carry out most cellular processes and are the direct targets of the vast majority of cancer drugs. By analyzing the protein landscape of a tumour, researchers can gain insights into its metabolic pathways, signaling networks, and potential vulnerabilities that might be missed by genetic sequencing alone.
Coupled with proteomics, the team utilized patient-derived tumour avatars grown on chicken eggs. This sophisticated model allows for the rapid, real-time testing of various drug candidates against a living, replicating piece of the patient’s actual tumour. This provides an invaluable preclinical platform to assess drug efficacy and identify personalized treatment responses in a matter of weeks, a speed unattainable through traditional in vivo animal models which can take months.
The Patient’s Journey: A Case Study in Persistence
The impetus for this research arose from the urgent needs of an unnamed young patient diagnosed with a rare and aggressive pediatric cancer. This patient’s tumour proved resistant to conventional chemotherapy regimens, leading to a desperate search for alternative treatments. Initial genomic profiling, while informative, failed to yield clear, actionable drug candidates after standard therapies had faltered and the tumour had developed resistance to a genomics-guided drug. This is a common and heartbreaking scenario in pediatric oncology, where time is a luxury that many patients do not possess.
Faced with a diminishing array of options, the multidisciplinary team, comprised of clinicians and researchers, made the pivotal decision to pivot from a solely genomic approach to incorporate proteomics. This decision, born out of clinical necessity and scientific foresight, ultimately proved to be a turning point in the patient’s treatment trajectory.
Unlocking Tumour Weaknesses: The Power of Proteomics
At the heart of this breakthrough was the meticulous proteomic analysis conducted by co-lead authors Dr. Georgina Barnabas, a postdoctoral researcher in Dr. Philipp Lange’s lab, and Tariq Bhat, a PhD student in Dr. James Lim’s lab. Their investigation delved into the functional machinery of the patient’s resistant tumour. While genes provide the instructions, proteins are the actual executors of cellular life, and most therapeutic drugs exert their effects by modulating protein activity. The hypothesis was that by examining the proteome, hidden metabolic dependencies or protein vulnerabilities could be unmasked.
This hypothesis proved correct. The proteomic analysis revealed a critical metabolic weakness: the tumour’s high reliance on an enzyme called SHMT2 (Serine Hydroxymethyltransferase 2). SHMT2 plays a crucial role in one-carbon metabolism, a pathway essential for cell growth and proliferation, particularly in rapidly dividing cancer cells. By identifying SHMT2 as a metabolic linchpin, the team had found a potential Achilles’ heel in the tumour that genomics had overlooked.
"With genomics alone, we couldn’t find a clear treatment option," stated Dr. Lange, a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR, alongside Dr. Lim and clinician Dr. Rebecca Deyell. "But by looking at the tumour’s proteins, we found a critical metabolic weakness that we could target with an already approved drug." This discovery was significant because it pointed towards a specific vulnerability that could be exploited therapeutically.
The researchers then strategically identified sertraline, a common antidepressant, as a drug capable of inhibiting SHMT2. This repurposing of an existing, FDA-approved drug offered a distinct advantage: its safety profile and pharmacokinetics were already well-established, potentially accelerating its clinical application for this patient. The rationale was simple yet profound: by inhibiting SHMT2, sertraline could effectively cut off the tumour’s access to a key energy source, thereby hindering its growth and survival.
The Chicken Egg Avatar: A Rapid Testing Ground
Having identified a promising drug candidate through proteomics, the next critical step was to validate its efficacy against the patient’s specific tumour. This is where the innovative chicken egg avatar model came into play. The team employed a method involving the transplantation of a small piece of the patient’s tumour onto the chorioallantoic membrane (CAM) of a fertilized chicken egg. This ex ovo model essentially creates a living "avatar" of the patient’s tumour, allowing it to grow and behave much like it would within the patient, but in an accessible and controllable environment.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," explained Dr. Lim. "We could quickly confirm whether the drug we identified through proteomics could actually work for the patient’s tumour." The ability to test personalized drug responses within weeks, rather than months, is a game-changer for patients facing aggressive and rapidly progressing cancers. Traditional methods, such as in vitro cell lines or in vivo mouse models, often require more time and may not always accurately reflect the tumour’s behavior within the human body. The chicken egg avatar provides a unique compromise, offering rapid results with a high degree of physiological relevance.
This advanced ex ovo model is an integral part of the BRAvE initiative (Better Responses through Avatars and Evidence) at BCCHR, a program specifically designed to bridge the gap between cutting-edge research labs and clinical patient care at the hospital. BRAvE exemplifies the commitment to translating scientific discoveries into tangible benefits for patients with the utmost urgency.
A Collaborative Triumph: PROFYLE and ACCESS Initiatives
The success of this personalized treatment strategy is not merely a testament to the ingenuity of the UBC and BCCHR researchers but also highlights the power of collaborative science within Canada. The work was a direct output of PROFYLE (PRecision Oncology For Young peopLE), a flagship initiative of ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). ACCESS serves as Canada’s overarching pediatric cancer network, bringing together a formidable alliance of over 30 research and funding organizations and more than 100 investigators from across the nation.
PROFYLE’s mission is explicitly to improve cancer outcomes for children and young adults by accelerating the adoption of precision oncology. Its structure facilitates rapid sharing of clinical samples, genomic and proteomic data, and expert consultation across diverse institutions. This collaborative framework was critical for the current study, enabling the rapid transfer of patient samples, specialized proteomic analysis, and the subsequent expert review process. Without such a robust national network, the intricate coordination required for this personalized approach would be significantly more challenging, if not impossible.
Leaders within the PROFYLE and ACCESS initiatives have consistently emphasized the importance of such integrated research efforts. "This study is a powerful illustration of what can be achieved when Canada’s brightest minds and most dedicated institutions unite against childhood cancer," commented a representative from the PROFYLE steering committee, highlighting the initiative’s role in fostering a new era of precision medicine for young Canadians. "It demonstrates the tangible impact of our collaborative infrastructure in translating complex science into immediate clinical benefit."
Expert Endorsement and Clinical Application
Once the ex ovo avatar model confirmed sertraline’s efficacy against the patient’s tumour, the findings were presented to a panel of experts established by PROFYLE. This panel, composed of leading oncologists, pathologists, molecular biologists, and pharmacologists from across Canada, rigorously reviewed the proteomic data, the ex ovo model results, and the clinical context. Their consensus was unanimous: sertraline represented the most promising and best-justified treatment option for the patient at that critical juncture. This expert endorsement provided crucial validation for the novel approach and facilitated the rapid implementation of the treatment plan.
Initial Outcomes and Future Horizons
Following the PROFYLE panel’s recommendation, the patient began treatment with sertraline. The initial results were encouraging, offering a glimmer of hope in a previously bleak prognosis. The patient’s tumour growth slowed significantly, indicating that the targeted therapy was indeed having an impact. However, the treatment did not result in a complete cure, and the tumour growth did not entirely cease, meaning that additional therapeutic interventions would still be necessary in the future.
"While there is more work to be done, this study shows that our approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," affirmed Dr. Lange. The immediate benefit to the patient, despite not being a complete resolution, validated the entire methodology and provided invaluable proof-of-concept for its clinical utility. The team now harbours the ambitious goal of expanding this innovative method to other children across the country, aiming to identify effective treatments faster and more precisely for a broader spectrum of pediatric cancers.
Broader Implications for Personalized Cancer Therapy
The implications of this study extend far beyond a single patient’s case. It heralds a potential paradigm shift in personalized cancer medicine, moving beyond the sole reliance on genomics to integrate the dynamic and functional insights provided by proteomics. For rare and aggressive cancers, where every moment counts, this combined approach offers a powerful new weapon in the therapeutic arsenal.
- Enhanced Precision: By adding proteomics to genomics, clinicians gain a more comprehensive understanding of tumour biology, increasing the likelihood of identifying effective targets. This ‘multi-omic’ approach acknowledges the complexity of cancer and the limitations of single-platform analyses.
- Accelerated Drug Discovery and Repurposing: The rapid turnaround time offered by the ex ovo avatar model, combined with the ability to identify targets for existing, approved drugs (drug repurposing), significantly shortens the path from discovery to clinical application. This is particularly vital for pediatric oncology, where new drug development can be slow.
- Reduced Patient Burden: By quickly identifying potentially effective treatments, this approach can minimize the need for lengthy and often toxic trial-and-error chemotherapy regimens, improving the quality of life for young patients and their families.
- Cost-Effectiveness: While initial setup for advanced proteomic and avatar platforms can be substantial, the ability to avoid ineffective treatments and rapidly identify optimal therapies can lead to significant long-term cost savings in healthcare systems.
- Scalability and National Impact: The success within the PROFYLE framework demonstrates the feasibility of implementing such sophisticated precision medicine strategies on a national scale. Expanding this network could ensure equitable access to these advanced diagnostics and treatment planning tools for children across Canada, regardless of their geographical location.
An independent expert in precision medicine, Dr. Evelyn Thorne, not involved in the study, commented on its significance: "This research represents a pivotal moment in personalized oncology. The integration of proteomics with rapid avatar models addresses critical unmet needs in pediatric cancer. It’s a testament to the innovative spirit required to tackle the most challenging forms of the disease and offers a beacon of hope for children whose options have historically been limited."
The Path Forward: Expanding Access and Refining Techniques
The journey, however, is far from over. Future research will focus on further refining both the proteomic analysis techniques and the ex ovo avatar models to enhance their predictive power and broaden their applicability to an even wider range of cancer types. Efforts will also be directed towards standardizing these methods to facilitate their integration into routine clinical practice across more institutions.
The ultimate vision is to establish a robust, pan-Canadian infrastructure where every young cancer patient, especially those with aggressive or relapsed disease, can benefit from this advanced, personalized approach. This will require continued collaboration, sustained funding for research initiatives like PROFYLE and ACCESS, and ongoing commitment from healthcare providers and policymakers to embrace and integrate these cutting-edge technologies. The work by the UBC and BCCHR team, supported by a powerful national network, illuminates a promising new path in the relentless fight against childhood cancer, offering not just treatment, but tailored hope.
